Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Norovirus Market Spotlight Report 2017 -

Research and Markets
Posted on: 15 Feb 18

The "Market Spotlight: Norovirus" report has been added to's offering.

This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, recent events, and an epidemiological overview.

Key Takeaways

  • Worldwide, about one out of every five cases of acute gastroenteritis is associated with norovirus. Norovirus is responsible for approximately 685 million cases of gastroenteritis every year.
  • Globally, norovirus is estimated to cause approximately 200,000 deaths annually, with 70,000 or more being children in developing countries.
  • There are currently two drug candidates in Phase II, and no drug candidates in Phase III. All of the drug candidates currently in the pipeline for norovirus are vaccines. These drugs are administered via oral, intranasal, and intramuscular routes.
  • The clinical trials distribution across Phase I-IV indicates that the majority of trials for norovirus have been in early and mid phases of development, with 91.2% of trials in Phase I-II, and only 8.8% in Phase III.
  • Clinical trial activity in the norovirus space is dominated by planned trials. Takeda has the highest number of planned clinical trials for norovirus, with 10 planned trials.
  • Takeda leads industry sponsors with by far the highest number of clinical trials for norovirus, followed by Vaxart and UMN Pharma.

Key Topics Covered:




Challenges for vaccine development


Norovirus outbreaks



Recent events



For more information about this report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.